Debbie Shawcross is a Clinician Scientist and Professor in Hepatology and Chronic Liver Failure at the Institute of Liver Studies (ILS), King’s College Hospital and the James Black Centre, King’s College London. She works as a Consultant Hepatologist on the King’s Liver Unit with a specialist interest in hepatic encephalopathy and the complications of cirrhosis. The aims of her research programme are to characterise the immunobiology of chronic liver failure focusing specifically on the gut-liver-brain axis in the context of the gut microbiome as a driver of immune dysfunction, inflammation, and encephalopathy.  She is also the Chief Investigator of the NIHR-funded EME UK multicentre randomised placebo-controlled clinical trial of faecal microbiota transplantation (capsules) [PROMISE Trial] in patients with metabolic-associated and alcohol-related cirrhosis.

Sara Montagnese is an Associate Professor of Medicine and Honorary Consultant Physician at Padova University Hospital, in Italy. From 1 June 2022 she will also be a part-time Full Professor of Chronobiology at the University of Surrey, in the UK. She is Past President of the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) and a member of the Governing Boards of the Italian Association for the Study of the Liver (AISF) and the European Biological Rhythms Society (EBRS). She is Associate Editor and Special Section Editor (Snapshots) of Journal of Hepatology, and Associate Editor of Frontiers in Physiology – Chronobiology. She has also been part of the Editorial Boards of Hepatology and BMJ-Open Gastroenterology.

Philipp Schwabl is a young physician-scientist, focusing on end-stage liver disease, portal hypertension and translational research. He had his training at the Medical University of Vienna and is currently an EASL Sheila Sherlock research fellow at the UCL Institute for Liver & Digestive Health in London. Being part of the EASL YI Task Force, he engages in making liver research more accessible and exciting for young investigators. 

Massimo Pinzani is Professor of Medicine at University College London (UCL), London, United Kingdom. He is a clinical and translational hepatologist, Sheila Sherlock Chair of Hepatology and Director of the UCL Institute for Liver and Digestive Health, Division of Medicine. He is also one of the pioneers in the research dedicated to cellular and molecular mechanisms of liver fibrosis and relative diagnostic and therapeutic approaches. His current research focus is regenerative medicine and on the development of extracellular matrix scaffold of liver, pancreas and small intestine for cell bioengineering and 3D disease modelling. He served as Educational Councillor and member of the governing board of the European Association for the Study of the Liver (EASL).

Aleksander Krag is Professor and Head of Hepatology at University of Southern Denmark and Odense University Hospital. Main research areas are within complications to cirrhosis, portal hypertension and alcoholic liver disease. He is involved in a number of collaborations, including being Coordinator in the H2020 project GALAXY: Gut and liver axis in alcoholic liver fibrosis.

Professor Dr Thomas Berg is Head of the Division of Hepatology, Department of Medicine II, at the Leipzig University Medical Center, Germany, and Chair of the University Liver Tumor Center, and Vice-Chair of the University Liver Transplant Center Leipzig. He is Secretary General of the European Associations for the Study of the Liver (EASL), Board member of the EASL International Liver Foundation (EILF) and served the Journal of Hepatology as Co-Editor between 2014 and 2019. He has published more than 440 articles in peer-reviewed journals and more than 100 reviews and textbook contributions. His h-index is 76 (Scopus). 

Dr Lok is currently Director of the Hepatology Program and Assistant Dean for Clinical Research at the University of Michigan. Her research focuses on natural history and treatment of hepatitis B and C and, more recently, includes liver cancer and fatty liver. She has mentored more than 60 fellows and junior faculty from all over the world and received many awards including an International Recognition Award from the European Association for the Study of the Liver in 2018, and a Distinguished University Professorship from the University of Michigan in 2019. Dr Lok served as Associate Editor of Hepatology in 2001-2006 and Senior Associate Editor of Gastroenterology in 2011-2012. Dr Lok served as AASLD President in 2017.

Professor Yuen is the Chair and Chief of the Division of Gastroenterology and Hepatology at the University of Hong Kong. His research interests include prevention, natural history, serology, virology and treatment of chronic hepatitis B and C, and hepatocellular carcinoma. He is one of the top internationally renowned researchers in the field of hepatitis B disease. As a world-class clinician scientist, Professor Yuen is now leading most of the international trials examining new drugs including antiviral and immunomodulatory agents for the treatment of chronic hepatitis B. He is also actively performing cutting edge research on novel markers for hepatitis B infection and occult hepatitis B infection.

Dr Patrizia Künzler-Heule is a Swiss registered nurse additionally prepared with a PhD in Nursing Science. For 25 years, she works in the clinic for Gastroenterology/Hepatology at the Cantonal Hospital St. Gallen. She has developed an advanced practice nurse role with a focus on nursing care for patients with chronic liver diseases. At the University of Basel, she is doing her research and give lectures especially on programs/interventions for enhanced self-management and behavioral change. Since 2020, she is chair of the EASL nurses & AHP taskforce.

Roz Davies is a General Manager and leads for the Royal Cornwall Hospitals Trust with the operational delivery of their Net Zero Green Plan. With 27 years of NHS grass roots experience and award winning sustainable credentials, practical, hard work has delivered the actions needed to create a Greener Cornwall and NHS.

Prof. Dr Tania Roskams is Head of the Department of Imaging and Pathology of the University of Leuven, Belgium. She also heads the research groups of Translational Cell-and Tissue Research and is a professor in Anatomy, Histology and Liver Pathology in the Medical Faculty of the same university. Prof. Roskams was an independent member of the Scientific Board of the United European Gastroenterology Federation (2005-2011) and a member of the Governing Board of the European Association for the Study of the Liver (2009-2012). Her research interests include liver stem/progenitor cells in liver regeneration and carcinogenesis. She also specialises in the characterisation of animal models of human diseases.

Prof. Darren Treanor is a consultant pathologist at Leeds Teaching Hospitals NHS Trust, honorary professor of pathology at the University of Leeds, adjunct professor in digital pathology at Linköping University, Sweden and Digital Pathology Lead for the UK Royal College of Pathologists. Dual qualified in medicine and computing, he has co-authored over 150 papers on digital pathology. He is director of the £50m National Pathology Imaging Co-operative which will deploy digital pathology across the North of England, and in two national networks supporting rare tumours - creating a unique national infrastructure for artificial intelligence.

Frank Tacke is board-certified in Internal Medicine, Gastroenterology, Endocrinology and Diabetology, Critical Care Medicine and Infectious Diseases. He has (co)authored >580 peer-reviewed original and review articles, and he is listed as a “Highly Cited Researcher 2020 and 2021” in the area “cross-field”. He has served on the Governing Board of the EASL (2014-2018) and is currently Co-Editor at the JHEP. Professor Tacke has been appointed in 2019 as the Head of Hepatology and Gastroenterology at the Charité - Universitätsmedizin Berlin, one of Europe’s largest university hospitals and renowned for excellence in medicine.

Dr Greten is co-chair of the Center of Excellence in Immunology, member of the Center for Advanced Preclinical Research oversight. In 2010 he joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015 and Deputy Branch Chief in 2018. Dr Greten has published more than 200 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC.

Prof. Mathias Heikenwaelder is a trained molecular biologist and microbiologist, with expertise in immunology, pathology and a strong link to translational research evoked by 10 years of work and expertise in a Pathology Institution (Clinical Pathology, University Hospital Zurich, Switzerland). Since October 2015 he is heads the Department “Chronic inflammation and Cancer” at the German Cancer Research Center (DKFZ) in Heidelberg focusing on the link between chronic inflammation and cancer, with the main focus on liver cancer. Prof. Heikenwaelder’s laboratory aims at understanding the different immune signatures of chronic inflammatory human diseases driving liver tissue damage and liver cancer using patient material and relevant preclinical mouse models. This is done with the final aim to generate valid pre-clinical models of chronic inflammation induced tissue damage and cancer, used for pre-clinical research. Mathias Heikenwälder has received several awards and prestigious grants (ERC-Starting 2011; ERC-Consolidator 2016; ERC-Proof of concept 2019; Horizon 2020, German Cancer Award 2022) and has become a highly cited researcher in 2019, 2020 and 2021. His credo is to support young researchers to follow their dreams and to support them to become independent.

Jessica Zucman-Rossi is Professor of Medicine at University Paris Descartes, within the department of Oncology at the European Hospital Georges Pompidou (AP-HP). She is the director of the Cordeliers Center of Research and of the team “Functional Genomics of Solid Tumors”, with a focus on liver and mesothelial tumors. Her team aims to develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis and to transfer this knowledge into biomarkers that could be introduced in clinical care. In particular, the group was pioneer in the elucidation of the molecular classification of benign and malignant liver tumors. Currently, she is President of the International Liver Cancer Association (ILCA) and she acts as Editor in Chief for the new EASL open access journal “JHEP Reports”.

Professor Jean-Francois Dufour studied mathematics at the University of Geneva, Switzerland, and received his medical degree from the Geneva Medical School. After training in internal medicine in Switzerland, he joined the laboratory of Professor I. Arias at Tufts University in Boston, Massachusetts, where he studied the effects of calcium signalling on bile canaliculus. He returned to the clinic to complete a gastroenterology fellowship with Professor M. Kaplan at the New England Medical Center. Then, Professor Dufour established his own laboratory at the University of Bern, Switzerland, where he was clinic director for 10 years. Professor Dufour is a member of the American Association for the Study of Liver Disease (fellow), the American Gastroenterology Association (fellow), the European Association for the Study of the Liver (EASL). He is a founding member of the International Liver Cancer Association. He was twice member of governing board of EASL as scientific committee member and then as educational councillor. He was member of the United European Gastroenterology educational committee. Professor Dufour has a large clinical experience and a broad understanding of basic and translational research, its bottleneck and the challenges in disseminating and exploiting knowledge. Professor Dufour has served as principal investigator on numerous clinical studies, focusing on NASH and hepatocellular carcinoma. He is an associate editor of GUT, and was an associate editor of Hepatology (responsible for the monthly ‘Highlights’ section), Journal of Hepatology and Liver International.

Daniél Vega Møller is Vice President in Clinical Drug Development, Obesity & NASH within Novo Nordisk A/S. He graduated in Medicine at the University of Copenhagen in 2000, where he also obtained his PhD within molecular cardio-genetics and heart failure. He has also been involved in the analysis of different biomarkers and their importance for prediction within the field of hypertension, CVD and obesity. After 10 years in the hospital setting in internal medicine, mainly cardiology, he moved to Novo Nordisk and has been employed for almost 12 years focusing on drug development within the portfolio of insulin, obesity and metabolism leading to approval of new drugs for the benefit of the people with chronic diseases. He is currently overall responsible for the departments driving the clinical development plans within obesity and NASH at the clinical stages of development from phase 1-4, including the exploration of possible diagnostic and prognostic biomarkers.